Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Standardized Reporting Forms for Food and Drug Administration Federally Funded Public Health Projects and Agreements, 73347-73348 [2023-23560]
Download as PDF
Federal Register / Vol. 88, No. 205 / Wednesday, October 25, 2023 / Notices
Dated: October 19, 2023.
Alison Barkoff,
Senior official performing the duties of the
Administrator and the Assistant Secretary for
Aging.
[FR Doc. 2023–23563 Filed 10–24–23; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0584]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Standardized
Reporting Forms for Food and Drug
Administration Federally Funded
Public Health Projects and Agreements
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing that a proposed collection
of information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
SUMMARY:
Submit written comments
(including recommendations) on the
collection of information by November
24, 2023.
DATES:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be submitted to https://
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
Review—Open for Public Comments’’ or
by using the search function. The OMB
control number for this information
collection is 0910–0909. Also include
the FDA docket number found in
brackets in the heading of this
document.
ADDRESSES:
lotter on DSK11XQN23PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
Rachel Showalter, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 240–994–7399, PRAStaff@
fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
17:01 Oct 24, 2023
Jkt 262001
Standardized Reporting Forms for FDA
Federally Funded Public Health
Projects
OMB Control Number 0910–0909—
Revision
This information collection supports
federally funded public health projects
administered by FDA. As part of FDA’s
efforts to protect the public health, we
work collaboratively with State partners
to enhance oversight of FDA-regulated
products. Consistent with applicable
regulations, we collect information
related to an awardee’s progress in
completing agreed-upon performance
metrics.
To increase our efficiency in
evaluating program effectiveness and
return-on-investment (ROI)/return-onvalue (ROV) for the federally funded
projects that we administer, we
developed and established the use of
digital forms under a pilot project
information collection that contain
tailored, standardized questions to
capture data elements necessary to
measure/track ROI/ROV, best practices,
and program effectiveness. Forms are
submitted by email and aggregated into
dynamic reports by program for FDA
evaluators allowing for quick
comparison of program data between
report periods and comparable metrics
to evaluate program success or lack of
performance in a timely manner. The
pilot project confirmed that the use of
standardized forms will reduce the time
required by awardees in completing and
submitting data collection reports.
Additional findings include: a drastic
increase in data quality, a significant
reduction in the number of follow-ups
needed to request additional
information or clarify responses, and the
ability to aggregate data quickly into a
useable format for programmatic review
and respond effectively to requests for
program performance data. Coupled
with positive feedback from FDA data
users and external partners received
during the pilot project, we considered
the pilot phase a success and plans to
continue use of tailored forms for
program performance metrics including
ROI/ROV data for its current and new
funded public health projects moving
forward.
Respondents complete an initial
report and progress/performance reports
which include data fields to identify the
award project and contact person and
directs specific questions to respondents
regarding project and progress updates.
As the public, partnering awardees, and
FDA data users provide feedback
through various opportunities, we will
revise the reports tailoring for project
specificity and purpose, to include, but
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
73347
not limited to, improvements in metrics
analysis, question clarity, and
formatting and design, such as dropdown menu selections and potential
common response indicators. This
method will ensure a continuation of
the reduced time for respondents and
allow us to more quickly process
information and determine impacts at
the Agency level as observed during the
pilot. As information will be requested
of actively funded projects, it still may
become necessary to request additional
information for a particular project to
complete the performance evaluation(s)
in a timely manner. To ensure data is
sufficient, on a case-by-case basis, FDA
anticipates a need for follow-up
questionnaire(s) to supplement the
progress reports and as instruments of
collection are developed and fine-tuned
through this effort. We do not have any
specific adjustments or revisions to the
approved forms at this time, other than
the inclusion of PRA statements. Due to
the evolving nature of public health
issues, non-substantive modifications
may be made to the forms during the 3year approval period of this information
collection. Prior to implementation,
such modifications will be submitted to
OMB for approval, and they will be
made available for public review and
comment during the standard
information collection extension/
revision approval process.
In the Federal Register of July 29,
2021 (86 FR 40853), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. No comments were
received. Subsequent to the close of the
60-day notice public comment period,
additional comments were received
from internal and external stakeholders
through our solicitation of feedback
external to the PRA public comment
opportunity. Upon our review, these
comments were generally supportive of
the piloted forms, and many contained
suggestions for additional technical
improvements. At the same time, none
of the comments suggested any change
to our estimated burden and we have
therefore retained those currently
submitted. While we are not making
changes to the forms with this
submission, we plan to implement
changes based on the feedback received
as part of the continuous improvement
process for the information collection
over the next few years.
Description of Respondents:
Respondents to the information
collection are State, local, Tribal and
Territorial governments who are
recipients of FDA-funded projects who
submit required information to FDA.
E:\FR\FM\25OCN1.SGM
25OCN1
73348
Federal Register / Vol. 88, No. 205 / Wednesday, October 25, 2023 / Notices
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Awardee activity
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average burden per response
Total hours
Initial Report; Update Reports; Supplement Reports (if applicable).
330
3.303
1,090
28.17 hours ......................................
(28 hours and 10 minutes) ...............
30,700
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
We estimate that 330 respondents will
participate in FDA funded projects and
agreements annually and will submit 2
to 4 reports within a single yearlong
budget period (Table 1). To ensure
adequate reporting will be achieved
over the course of these projects, the
option for a supplement report is
included in the estimated reporting
burden; however, the need for these
reports will be determined on a case-bycase basis with the FDA project
manager. The estimated burden for each
of the individual reporting activities
was calculated based on the annual
number of submissions and distributed
among respondents.
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Awardee activity
Number of
recordkeepers
Number of
records per
recordkeeper
Total annual
records
Average burden per recordkeeping
Total hours
Initial Report, Updated Reports, or
Supplement Reports (if applicable).
330
3.303
1,090
0.5 hours ..........................................
(30 minutes) .....................................
545
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Recordkeeping activities include
storing and maintaining records related
to submitting a request to participate in
the project and compiling reports.
Respondents should use current record
retention capabilities for electronic or
paper storage to achieve these activities.
We assume it will take 0.5 hour/year to
ensure the documents related to
submitting a request to participate in the
program are retained properly according
to their existing recordkeeping policies,
but no less than 3 years, as
recommended by FDA (Table 2). The
estimated burden for each of the
individual reporting activities was
calculated based on the annual number
of submissions and distributed among
respondents.
TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1
Awardee-entity activity
Number of
respondents
Number of
disclosures
per respondent
Total annual
disclosures
Average burden per disclosure
Total hours
Coordination with partnering entities
related to Initial Report, Update
Reports, and Supplement Report
(if applicable).
200
7
1,400
8 .......................................................
11,200
lotter on DSK11XQN23PROD with NOTICES1
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
For those funded projects that involve
a participant composed of partnering
entities in the program, FDA is taking
into consideration the time that
partnering entities will spend
coordinating with each other. We
estimate that 200 respondents will work
with their respective partnering entities
and the average number of partnering
entities will be 2. We assume each
respondent will spend 8 hours
coordinating with each partnering entity
on each response for an estimated 7
responses or reports each (Table 3). The
estimated burden for each of the
individual reporting activities was
calculated based on the annual number
VerDate Sep<11>2014
17:01 Oct 24, 2023
Jkt 262001
of submissions and distributed among
respondents.
We are requesting OMB approval for
conclusion of the pilot project and
continued use of the forms for
programmatic data collection needs.
There are no adjustments or revisions to
the estimated burden. However, this
request results in an adjustment
decrease in the number of responses, to
correct data-entry errors in the database
related to the previous submission to
OMB.
PO 00000
Frm 00040
Fmt 4703
Sfmt 9990
Dated: October 20, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–23560 Filed 10–24–23; 8:45 am]
BILLING CODE 4164–01–P
E:\FR\FM\25OCN1.SGM
25OCN1
Agencies
[Federal Register Volume 88, Number 205 (Wednesday, October 25, 2023)]
[Notices]
[Pages 73347-73348]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-23560]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0584]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Standardized
Reporting Forms for Food and Drug Administration Federally Funded
Public Health Projects and Agreements
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is
announcing that a proposed collection of information has been submitted
to the Office of Management and Budget (OMB) for review and clearance
under the Paperwork Reduction Act of 1995.
DATES: Submit written comments (including recommendations) on the
collection of information by November 24, 2023.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be submitted to https://www.reginfo.gov/public/do/PRAMain. Find this particular information
collection by selecting ``Currently under Review--Open for Public
Comments'' or by using the search function. The OMB control number for
this information collection is 0910-0909. Also include the FDA docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Rachel Showalter, Office of
Operations, Food and Drug Administration, Three White Flint North, 10A-
12M, 11601 Landsdown St., North Bethesda, MD 20852, 240-994-7399,
[email protected].
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Standardized Reporting Forms for FDA Federally Funded Public Health
Projects
OMB Control Number 0910-0909--Revision
This information collection supports federally funded public health
projects administered by FDA. As part of FDA's efforts to protect the
public health, we work collaboratively with State partners to enhance
oversight of FDA-regulated products. Consistent with applicable
regulations, we collect information related to an awardee's progress in
completing agreed-upon performance metrics.
To increase our efficiency in evaluating program effectiveness and
return-on-investment (ROI)/return-on-value (ROV) for the federally
funded projects that we administer, we developed and established the
use of digital forms under a pilot project information collection that
contain tailored, standardized questions to capture data elements
necessary to measure/track ROI/ROV, best practices, and program
effectiveness. Forms are submitted by email and aggregated into dynamic
reports by program for FDA evaluators allowing for quick comparison of
program data between report periods and comparable metrics to evaluate
program success or lack of performance in a timely manner. The pilot
project confirmed that the use of standardized forms will reduce the
time required by awardees in completing and submitting data collection
reports. Additional findings include: a drastic increase in data
quality, a significant reduction in the number of follow-ups needed to
request additional information or clarify responses, and the ability to
aggregate data quickly into a useable format for programmatic review
and respond effectively to requests for program performance data.
Coupled with positive feedback from FDA data users and external
partners received during the pilot project, we considered the pilot
phase a success and plans to continue use of tailored forms for program
performance metrics including ROI/ROV data for its current and new
funded public health projects moving forward.
Respondents complete an initial report and progress/performance
reports which include data fields to identify the award project and
contact person and directs specific questions to respondents regarding
project and progress updates. As the public, partnering awardees, and
FDA data users provide feedback through various opportunities, we will
revise the reports tailoring for project specificity and purpose, to
include, but not limited to, improvements in metrics analysis, question
clarity, and formatting and design, such as drop-down menu selections
and potential common response indicators. This method will ensure a
continuation of the reduced time for respondents and allow us to more
quickly process information and determine impacts at the Agency level
as observed during the pilot. As information will be requested of
actively funded projects, it still may become necessary to request
additional information for a particular project to complete the
performance evaluation(s) in a timely manner. To ensure data is
sufficient, on a case-by-case basis, FDA anticipates a need for follow-
up questionnaire(s) to supplement the progress reports and as
instruments of collection are developed and fine-tuned through this
effort. We do not have any specific adjustments or revisions to the
approved forms at this time, other than the inclusion of PRA
statements. Due to the evolving nature of public health issues, non-
substantive modifications may be made to the forms during the 3-year
approval period of this information collection. Prior to
implementation, such modifications will be submitted to OMB for
approval, and they will be made available for public review and comment
during the standard information collection extension/revision approval
process.
In the Federal Register of July 29, 2021 (86 FR 40853), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received. Subsequent to the
close of the 60-day notice public comment period, additional comments
were received from internal and external stakeholders through our
solicitation of feedback external to the PRA public comment
opportunity. Upon our review, these comments were generally supportive
of the piloted forms, and many contained suggestions for additional
technical improvements. At the same time, none of the comments
suggested any change to our estimated burden and we have therefore
retained those currently submitted. While we are not making changes to
the forms with this submission, we plan to implement changes based on
the feedback received as part of the continuous improvement process for
the information collection over the next few years.
Description of Respondents: Respondents to the information
collection are State, local, Tribal and Territorial governments who are
recipients of FDA-funded projects who submit required information to
FDA.
[[Page 73348]]
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Awardee activity Number of responses per Total annual Average burden per response Total hours
respondents respondent responses
--------------------------------------------------------------------------------------------------------------------------------------------------------
Initial Report; Update Reports; Supplement 330 3.303 1,090 28.17 hours....................... 30,700
Reports (if applicable). (28 hours and 10 minutes).........
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
We estimate that 330 respondents will participate in FDA funded
projects and agreements annually and will submit 2 to 4 reports within
a single yearlong budget period (Table 1). To ensure adequate reporting
will be achieved over the course of these projects, the option for a
supplement report is included in the estimated reporting burden;
however, the need for these reports will be determined on a case-by-
case basis with the FDA project manager. The estimated burden for each
of the individual reporting activities was calculated based on the
annual number of submissions and distributed among respondents.
Table 2--Estimated Annual Recordkeeping Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Awardee activity Number of records per Total annual Average burden per recordkeeping Total hours
recordkeepers recordkeeper records
--------------------------------------------------------------------------------------------------------------------------------------------------------
Initial Report, Updated Reports, or Supplement 330 3.303 1,090 0.5 hours......................... 545
Reports (if applicable). (30 minutes)......................
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Recordkeeping activities include storing and maintaining records
related to submitting a request to participate in the project and
compiling reports. Respondents should use current record retention
capabilities for electronic or paper storage to achieve these
activities. We assume it will take 0.5 hour/year to ensure the
documents related to submitting a request to participate in the program
are retained properly according to their existing recordkeeping
policies, but no less than 3 years, as recommended by FDA (Table 2).
The estimated burden for each of the individual reporting activities
was calculated based on the annual number of submissions and
distributed among respondents.
Table 3--Estimated Annual Third-Party Disclosure Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Awardee-entity activity Number of disclosures per Total annual Average burden per disclosure Total hours
respondents respondent disclosures
--------------------------------------------------------------------------------------------------------------------------------------------------------
Coordination with partnering entities related to 200 7 1,400 8................................. 11,200
Initial Report, Update Reports, and Supplement
Report (if applicable).
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
For those funded projects that involve a participant composed of
partnering entities in the program, FDA is taking into consideration
the time that partnering entities will spend coordinating with each
other. We estimate that 200 respondents will work with their respective
partnering entities and the average number of partnering entities will
be 2. We assume each respondent will spend 8 hours coordinating with
each partnering entity on each response for an estimated 7 responses or
reports each (Table 3). The estimated burden for each of the individual
reporting activities was calculated based on the annual number of
submissions and distributed among respondents.
We are requesting OMB approval for conclusion of the pilot project
and continued use of the forms for programmatic data collection needs.
There are no adjustments or revisions to the estimated burden. However,
this request results in an adjustment decrease in the number of
responses, to correct data-entry errors in the database related to the
previous submission to OMB.
Dated: October 20, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-23560 Filed 10-24-23; 8:45 am]
BILLING CODE 4164-01-P